7/9
10:14 am
alec
GSK Walks Away From Alector - Pipeline Reset Story Begins [Seeking Alpha]
Medium
Report
GSK Walks Away From Alector - Pipeline Reset Story Begins [Seeking Alpha]
5/7
05:32 pm
alec
Alector GAAP EPS of -$0.21 beats by $0.06, revenue of $1.05M misses by $9.98M [Seeking Alpha]
High
Report
Alector GAAP EPS of -$0.21 beats by $0.06, revenue of $1.05M misses by $9.98M [Seeking Alpha]
5/7
04:05 pm
alec
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
High
Report
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
5/6
06:00 am
alec
Alector (ALEC) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
Low
Report
Alector (ALEC) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
4/29
04:05 pm
alec
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
High
Report
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis